208 related articles for article (PubMed ID: 36064607)
1. Comparison of growth dynamics in different types of MPS: an attempt to explain the causes.
Różdżyńska-Świątkowska A; Zielińska A; Tylki-Szymańska A
Orphanet J Rare Dis; 2022 Sep; 17(1):339. PubMed ID: 36064607
[TBL] [Abstract][Full Text] [Related]
2. Mental retardation in mucopolysaccharidoses correlates with high molecular weight urinary heparan sulphate derived glucosamine.
Coppa GV; Gabrielli O; Zampini L; Maccari F; Mantovani V; Galeazzi T; Santoro L; Padella L; Marchesiello RL; Galeotti F; Volpi N
Metab Brain Dis; 2015 Dec; 30(6):1343-8. PubMed ID: 26016623
[TBL] [Abstract][Full Text] [Related]
3. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
[TBL] [Abstract][Full Text] [Related]
4. Mucopolysaccharidoses and the eye.
Ashworth JL; Biswas S; Wraith E; Lloyd IC
Surv Ophthalmol; 2006; 51(1):1-17. PubMed ID: 16414358
[TBL] [Abstract][Full Text] [Related]
5. Further electroretinographic studies of patients with mucopolysaccharidoses.
Leung LS; Weinstein GW; Hobson RR
Birth Defects Orig Artic Ser; 1971 Mar; 7(3):32-40. PubMed ID: 5006141
[TBL] [Abstract][Full Text] [Related]
6. Parents' experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS).
Somanadhan S; Larkin PJ
Orphanet J Rare Dis; 2016 Oct; 11(1):138. PubMed ID: 27724940
[TBL] [Abstract][Full Text] [Related]
7. Validation of Liquid Chromatography-Tandem Mass Spectrometry-Based 5-Plex Assay for Mucopolysaccharidoses.
Oguni T; Tomatsu S; Tanaka M; Orii K; Fukao T; Watanabe J; Fukuda S; Notsu Y; Vu DC; Can TBN; Nagai A; Yamaguchi S; Taketani T; Gelb MH; Kobayashi H
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32188102
[TBL] [Abstract][Full Text] [Related]
8. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratorial study of 19 cases of mucopolysaccharidoses.
Albano LM; Sugayama SS; Bertola DR; Andrade CE; Utagawa CY; Puppi F; Nader HB; Toma L; Coelho J; Leistner S; Burin M; Giugliani R; Chong AK
Rev Hosp Clin Fac Med Sao Paulo; 2000; 55(6):213-8. PubMed ID: 11313661
[TBL] [Abstract][Full Text] [Related]
10. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
Zhang H; Wood T; Young SP; Millington DS
Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
[TBL] [Abstract][Full Text] [Related]
11. [Mucopolysaccharidosis: clinical features, diagnosis and management].
Suarez-Guerrero JL; Gómez Higuera PJ; Arias Flórez JS; Contreras-García GA
Rev Chil Pediatr; 2016; 87(4):295-304. PubMed ID: 26613630
[TBL] [Abstract][Full Text] [Related]
12. Rapid identification of San Filippo disease (MPS III).
Kelly S; Schedlbauer L; Leikhim E
Health Lab Sci; 1978 Jul; 15(3):123-7. PubMed ID: 151669
[TBL] [Abstract][Full Text] [Related]
13. Incidence of the mucopolysaccharidoses in Northern Ireland.
Nelson J
Hum Genet; 1997 Dec; 101(3):355-8. PubMed ID: 9439667
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of mucopolysaccharidoses.
Khan SA; Peracha H; Ballhausen D; Wiesbauer A; Rohrbach M; Gautschi M; Mason RW; Giugliani R; Suzuki Y; Orii KE; Orii T; Tomatsu S
Mol Genet Metab; 2017 Jul; 121(3):227-240. PubMed ID: 28595941
[TBL] [Abstract][Full Text] [Related]
15. Otorhinolaryngological manifestations in 61 patients with mucopolysaccharidosis.
Murgasova L; Jurovcik M; Jesina P; Malinova V; Bloomfield M; Zeman J; Magner M
Int J Pediatr Otorhinolaryngol; 2020 Aug; 135():110137. PubMed ID: 32502916
[TBL] [Abstract][Full Text] [Related]
16. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
[TBL] [Abstract][Full Text] [Related]
17. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
[TBL] [Abstract][Full Text] [Related]
18. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
[TBL] [Abstract][Full Text] [Related]
19. Incidence of the mucopolysaccharidoses in Western Australia.
Nelson J; Crowhurst J; Carey B; Greed L
Am J Med Genet A; 2003 Dec; 123A(3):310-3. PubMed ID: 14608657
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis.
Chuang CK; Lin SP; Chung SF
Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jan; 64(1):15-22. PubMed ID: 11310367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
